Rhythm Pharmaceuticals (RYTM) PT Raised to $72 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts RYTM Hot Sheet
Price: $86.44 -7.49%
Rating Summary:
19 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
19 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
Morgan Stanley analyst Jeffrey Hung raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $72.00 (from $55.00) while maintaining a Overweight rating.
You May Also Be Interested In
- RBC Capital Reiterates Outperform Rating on Rhythm Pharmaceuticals (RYTM)
- AMD (AMD) PT Raised to $725 at Stifel
- Rhythm Pharmaceuticals revises LG Chem license deal, secures $750M loan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
